These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 10545680)

  • 21. Comparison of "accelerated" tissue plasminogen activator with streptokinase for treatment of suspected myocardial infarction.
    Kellett J; Clarke J
    Med Decis Making; 1995; 15(4):297-310. PubMed ID: 8544674
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Survival outcomes 1 year after reperfusion therapy with either alteplase or reteplase for acute myocardial infarction: results from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) III Trial.
    Topol EJ; Ohman EM; Armstrong PW; Wilcox R; Skene AM; Aylward P; Simes J; Dalby A; Betriu A; Bode C; White HD; Hochman JS; Emanuelson H; Vahanian A; Sapp S; Stebbins A; Moliterno DJ; Califf RM
    Circulation; 2000 Oct; 102(15):1761-5. PubMed ID: 11023929
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship of plasminogen activator inhibitor-1 levels following thrombolytic therapy with rt-PA as compared to streptokinase and patency of infarct related coronary artery.
    Paganelli F; Alessi MC; Morange P; Maixent JM; Lévy S; Vague IJ
    Thromb Haemost; 1999 Jul; 82(1):104-8. PubMed ID: 10456462
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Streptokinase-induced hypotension has no detrimental effect on patients with thrombolytic treatment for acute myocardial infarction. A substudy of the Romanian Study for Accelerated Streptokinase in Acute Myocardial Infarction (ASK-ROMANIA).
    Tatu-Chiţoiu G; Teodorescu C; Dan M; Guran M; Căpraru P; Istrăţescu O; Tatu-Chiţoiu A; Bumbu A; Chioncel V; Arvanitopol S; Dorobanţu M
    Rom J Intern Med; 2004; 42(3):557-73. PubMed ID: 16366130
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Medical decision making in the choice of a thrombolytic agent for acute myocardial infarction. Quebec Acute Coronary Care Working Group.
    Brophy JM; Joseph L; Theroux P
    Med Decis Making; 1999; 19(4):411-8. PubMed ID: 10520679
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Time to treatment with thrombolytic therapy: determinants and effect on short-term nonfatal outcomes of acute myocardial infarction. Canadian GUSTO Investigators. Global Utilization of Streptokinase and + PA for Occluded Coronary Arteries.
    Cox JL; Lee E; Langer A; Armstrong PW; Naylor CD
    CMAJ; 1997 Feb; 156(4):497-505. PubMed ID: 9054819
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk factors for intracranial hemorrhage and nonhemorrhagic stroke after fibrinolytic therapy (from the GUSTO-i trial).
    Kandzari DE; Granger CB; Simoons ML; White HD; Simes J; Mahaffey KW; Gore J; Weaver WD; Longstreth WT; Stebbins A; Lee KL; Califf RM; Topol EJ;
    Am J Cardiol; 2004 Feb; 93(4):458-61. PubMed ID: 14969623
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stroke in patients treated with thrombolytic therapy for acute myocardial infarction. The thrombosis in myocardial infarction clinical trial and a review of placebo-controlled trials.
    Price TR
    Stroke; 1990 Nov; 21(11 Suppl):III8-9. PubMed ID: 2122557
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction.
    Krumholz HM; Pasternak RC; Weinstein MC; Friesinger GC; Ridker PM; Tosteson AN; Goldman L
    N Engl J Med; 1992 Jul; 327(1):7-13. PubMed ID: 1598117
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lessons we have learned from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries.
    Holmes DR; Califf RM; Topol EJ
    J Am Coll Cardiol; 1995 Jun; 25(7 Suppl):10S-17S. PubMed ID: 7775708
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advances in thrombolytic therapy for acute myocardial infarction.
    Topol EJ
    J Clin Pharmacol; 1987 Oct; 27(10):735-45. PubMed ID: 3123526
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pitfalls in the economic evaluation of thrombolysis in myocardial infarction. The impact of national differences in the cost of thrombolytics and of differences in the efficacy across patient subgroups.
    Lorenzoni R; Pagano D; Mazzotta G; Rosen SD; Fattore G; De Caterina R; Gensini G
    Eur Heart J; 1998 Oct; 19(10):1518-24. PubMed ID: 9820990
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries. Results from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
    Van de Werf F; Topol EJ; Lee KL; Woodlief LH; Granger CB; Armstrong PW; Barbash GI; Hampton JR; Guerci A; Simes RJ
    JAMA; 1995 May 24-31; 273(20):1586-91. PubMed ID: 7745771
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patient reperfusion preferences in acute myocardial infarction: mortality versus stroke, benefits versus costs, high technology versus drugs.
    Tsui W; Pierre K; Massel D
    Can J Cardiol; 2005 Apr; 21(5):423-31. PubMed ID: 15861260
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Coronary revascularization surgery after myocardial infarction: impact of bypass surgery on survival after thrombolysis. GUSTO Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
    Tardiff BE; Califf RM; Morris D; Bates E; Woodlief LH; Lee KL; Green C; Rutsch W; Betriu A; Aylward PE; Topol EJ
    J Am Coll Cardiol; 1997 Feb; 29(2):240-9. PubMed ID: 9014973
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: review of ocular hemorrhage incidence and location in the GUSTO-I trial. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries.
    Mahaffey KW; Granger CB; Toth CA; White HD; Stebbins AL; Barbash GI; Vahanian A; Topol EJ; Califf RM
    J Am Coll Cardiol; 1997 Dec; 30(7):1606-10. PubMed ID: 9385883
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [t-PA in thrombolytic therapy of acute myocardial infarct].
    Rutsch W; Schmutzler H
    Herz; 1994 Dec; 19(6):336-52. PubMed ID: 7843690
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thrombolytic therapy in Europe: current status.
    Vahanian A
    Eur Heart J; 1996 Sep; 17 Suppl E():21-7. PubMed ID: 11824000
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Coronary thrombolysis: streptokinase or recombinant tissue-type plasminogen activator?
    Collen D
    Ann Intern Med; 1990 Apr; 112(7):529-38. PubMed ID: 2107781
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potential cost effectiveness of tissue plasminogen activator among patients previously treated with streptokinase.
    Massel D
    Can J Cardiol; 1999 Feb; 15(2):173-9. PubMed ID: 10079776
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.